Tricyclic WRN Modulators for Selective MSI-H Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for DNA mismatch repair-deficient and microsatellite instability-high (dMMR/MSI-H) tumors, such as colorectal and ovarian cancers, have modest response rates and are poorly tolerated by patients, necessitating alternative therapies that target Werner helicase (WRN) to resolve toxic DNA structures and induce apoptosis in cancer cells without affecting normal tissues.
Innovation Solution
Development of small molecule modulators, specifically tricyclic derivatives, to selectively inhibit WRN helicase activity in MSI-H cancer cells, thereby inducing DNA damage and apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapeutic regimens or checkpoint inhibitors are used to treat dMMR/MSI-H tumors, then some tumor response is achieved, but the treatments are poorly tolerated by patients with modest long term response rates
Solution Approach 1:
The patent changes the molecular target parameter from general DNA repair pathways or immune checkpoint to specifically Werner helicase (WRN) in dMMR/MSI-H tumors. This selective parameter change allows the therapy to exploit the unique vulnerability of these tumors while avoiding the broad toxicity of conventional chemotherapies, achieving both high reliability response and improved patient tolerance.
Solution Approach 2:
The patent introduces small molecule WRN helicase inhibitors as intermediary agents that selectively disrupt the function of WRN in dMMR/MSI-H tumors. These intermediaries accumulate toxic DNA structures specifically in tumor cells with defective MMR, leading to selective cell death without affecting normal tissues, thus resolving the contradiction between efficacy and tolerance.
2Reliability
If anti-PD1 checkpoint inhibitors are used to treat MSI-H cancers, then tumor-specific neoantigens are targeted, but about half of dMMR/MSI tumors do not respond
Solution Approach 1:
The patent segments the treatment approach by identifying and targeting a specific subset of tumors (dMMR/MSI-H) that have a unique vulnerability in WRN helicase function. This segmentation allows for highly reliable response in the targeted population while acknowledging that not all MSI-H tumors may respond, thus addressing both the high response rate in selected patients and the limitation in universal adaptability.
Solution Approach 2:
The patent applies local quality by focusing the therapeutic action specifically on dMMR/MSI-H tumors that harbor WRN essentiality, rather than treating all cancer types uniformly. This localized approach maximizes response reliability in the selected patient population while accepting that the therapy is not universally adaptable to all tumor types, thereby optimizing the benefit-risk ratio for the intended indication.
3Reliability
If WRN helicase is inhibited to induce apoptosis in MSI-H cells, then selective tumor killing is achieved, but the mechanism must be carefully controlled to avoid affecting normal tissues
Solution Approach 1:
The patent employs local quality by designing WRN inhibitors that selectively target dMMR/MSI-H tumors based on their unique dependency on WRN helicase function. The therapy exploits the local difference in MMR status between tumor and normal tissues, achieving reliable selective killing in tumors while minimizing harm to normal tissues that maintain functional MMR pathways.
Solution Approach 2:
The patent converts the harmful effect of WRN inhibition (which would cause general DNA damage) into a beneficial selective toxic effect by exploiting the pre-existing deficiency in MMR pathways within dMMR/MSI-H tumors. The inhibition of WRN, which would normally be harmful, becomes selectively beneficial because it accumulates toxic DNA structures that normal cells with functional MMR can repair, thus achieving selective tumor killing with reduced normal tissue toxicity.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating Werner Helicase (WRN) activity and may be used in the treatment of disorders in which WRN activity is implicated, such as cancer.